Around 1 in 5 women with ovariancancer have BRCA mutations. Testing for the mutation presence and type is key to assessing both cancer risk and the ideal treatment pathway. ASCO19 OCSMpic.twitter.com8BxcfH7Bh6

Around 1 in 5 women with #ovariancancer have BRCA mutations. Testing for the mutation presence and type is key to assessing both cancer risk and the ideal treatment pathway. #ASCO19 #OCSMpic.twitter.com/8BxcfH7Bh6

17:15 EDT 3 Jun 2019 | AztraZeneca

Around 1 in 5 women with #ovariancancer have BRCA mutations. Testing for the mutation presence and type is key to assessing both cancer risk and the ideal treatment pathway. #ASCO19 #OCSM pic.twitter.com/8BxcfH7Bh6

More From BioPortfolio on "Around 1 in 5 women with #ovariancancer have BRCA mutations. Testing for the mutation presence and type is key to assessing both cancer risk and the ideal treatment pathway. #ASCO19 #OCSMpic.twitter.com/8BxcfH7Bh6"